Search results for "porter"

showing 10 items of 920 documents

Lack of Hypoxic Response in Uterine Leiomyomas despite Severe Tissue Hypoxia

2008

Abstract Hypoxia is now established as a key factor influencing the pathophysiology of malignant growth. Among other effects, hypoxia modulates the expression of a multitude of genes through the induction of hypoxia-inducible transcription factors. This differential gene expression favors angiogenesis, cell survival, an invasive/metastatic phenotype, and resistance to anticancer therapies. Because benign tumors do not exhibit these traits, one might expect these entities to be neither hypoxic nor to induce the genetic hypoxia response program. To test this hypothesis, an investigation of the oxygenation status of 17 leiomyomas and 1 leiomyosarcoma of the uterus using polarographic needle el…

AdultLeiomyosarcomaLeiomyosarcomaCancer ResearchPathologymedicine.medical_specialtyAngiogenesisUterusUterine Cervical NeoplasmsApoptosisBiologyImmunoenzyme TechniquesAntigens NeoplasmBiopsyBasic Helix-Loop-Helix Transcription FactorsIn Situ Nick-End LabelingmedicineHumansProspective StudiesCarbonic Anhydrase IXHypoxiaCarbonic AnhydrasesCell ProliferationGlucose Transporter Type 1Uterine leiomyomaLeiomyomamedicine.diagnostic_testMiddle AgedHypoxia (medical)Hypoxia-Inducible Factor 1 alpha Subunitmedicine.diseasePhenotypeOxygenmedicine.anatomical_structureLeiomyomaOncologyMyometriumFemalemedicine.symptomCancer Research
researchProduct

Cholelithiasis in Patients with Gaucher Disease type 1: Risk Factors and the Role of ABCG5/ABCG8 Gene Variants

2016

Background & Aim: Patients with Gaucher disease type 1 (GD1) show an altered lipid profile and a certain degree of insulin resistance, which might contribute to cholelithiasis (CL) and could possibly be associated with ABCG5/ABCG8 gene variants. We aimed to investigate the prevalence of CL in Caucasian adult patients with GD1 and the possible risk factors, including gene variants of the ABCG5/ABCG8 genes.
 Methods: 61 Caucasian patients with GD1 (38 female/23male), aged 18-62 years and 61 healthy subjects matched for age, gender and BMI, without CL, for comparison of lipid profiles. Data before start of enzyme replacement therapy (ERT) were recorded: clinical, haematological, sever…

AdultMale0301 basic medicineHeterozygotemedicine.medical_specialtyAdolescentLipoproteinsmedicine.medical_treatmentSplenectomyABCG8030105 genetics & heredityGastroenterologyWhite PeopleYoung Adult03 medical and health sciencesInsulin resistanceGene FrequencyCholelithiasisRisk FactorsInternal medicineGenotypePrevalencemedicineHumansEnzyme Replacement TherapyGenetic Predisposition to DiseaseATP Binding Cassette Transporter Subfamily G Member 5Genetic Association StudiesGaucher Diseasemedicine.diagnostic_testRomaniabusiness.industryATP Binding Cassette Transporter Subfamily G Member 8HomozygoteGastroenterologyCase-control studyGenetic VariationEnzyme replacement therapyMiddle Agedmedicine.diseaseCross-Sectional StudiesPhenotypeCase-Control StudiesGlucosylceramidaseFemaleLipid profilebusinessDyslipidemiaJournal of Gastrointestinal and Liver Diseases
researchProduct

Erratum to: Donor age and long-term culture do not negatively influence the stem potential of limbal fibroblast-like stem cells

2016

In regenerative medicine the maintenance of stem cell properties is of crucial importance. Ageing is considered a cause of reduced stemness capability. The limbus is a stem niche of easy access and harbors two stem cell populations: epithelial stem cells and fibroblast-like stem cells. Our aim was to investigate whether donor age and/or long-term culture have any influence on stem cell marker expression and the profiles in the fibroblast-like stem cell population.Fibroblast-like stem cells were isolated and digested from 25 limbus samples of normal human corneo-scleral rings and long-term cultures were obtained. SSEA4 expression and sphere-forming capability were evaluated; cytofluorimetric…

AdultMale0301 basic medicineStage-Specific Embryonic AntigensPrimary Cell CultureGene ExpressionMedicine (miscellaneous)Limbus CorneaeBiologyBiochemistry Genetics and Molecular Biology (miscellaneous)Donor age03 medical and health sciencesCell MovementSpheroids CellularmedicineATP Binding Cassette Transporter Subfamily G Member 2HumansFibroblastAgedCell ProliferationStem CellsAge FactorsEpithelium CornealCell DifferentiationEpithelial CellsHLA-DR AntigensNanog Homeobox ProteinCell BiologyFibroblastsMiddle AgedMolecular medicinehumanitiesNeoplasm ProteinsCell biology030104 developmental biologymedicine.anatomical_structureLeukocyte Common AntigensMolecular MedicineFemaleErratumStem cellOctamer Transcription Factor-3BiomarkersStem Cell Research & Therapy
researchProduct

Lomitapide affects HDL composition and function

2016

Abstract Background Lomitapide reduces low-density lipoprotein-cholesterol (LDL-C) but also high-density lipoprotein-cholesterol (HDL-C) levels. The latter may reduce the clinical efficacy of lomitapide. We investigated the effect of lomitapide on HDL-C levels and on cholesterol efflux capacity (CEC) of HDL in patients with homozygous familial hypercholesterolemia (HoFH). Methods and results Four HoFH patients were treated with increasing dosages of lomitapide. Lomitapide decreased LDL-C (range −34 to −89%). Total HDL-C levels decreased (range −16 to −34%) with a shift to buoyant HDL. ABCA1-mediated CEC decreased in all patients (range −39 to −99%). The changes of total, ABCG1- and SR-BI-me…

AdultMale0301 basic medicinemedicine.medical_specialtySettore MED/09 - Medicina InternaHDLHomozygous familial hypercholesterolemiaFamilial hypercholesterolemia030204 cardiovascular system & hematologyHyperlipoproteinemia Type IIYoung Adult03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineHumansMedicineIn patientClinical efficacyHyperlipoproteinemia Type IICholesterolbusiness.industryCholesterol HDLHomozygotenutritional and metabolic diseasesCholesterol LDLCholesterol efflux capacityAtherosclerosismedicine.diseaseCholesterol lowering drugsLomitapideLomitapideCholesterolPhenotypeTreatment Outcome030104 developmental biologyEndocrinologychemistryBenzimidazolesFemalelipids (amino acids peptides and proteins)Composition (visual arts)Cholesterol lowering drugHydroxymethylglutaryl-CoA Reductase InhibitorsLipoproteins HDLCardiology and Cardiovascular MedicinebusinessATP Binding Cassette Transporter 1Atherosclerosis
researchProduct

Effect of single-dose and short-term administration of quercetin on the pharmacokinetics of talinolol in humans – Implications for the evaluation of …

2013

Quercetin has been shown to inhibit intestinal P-glycoprotein-mediated drug efflux. A crossover clinical study was performed in 10 healthy volunteers to assess the effect of single-dose and repeated quercetin intake on the pharmacokinetics of talinolol, a substrate of intestinal P-glycoprotein. Unexpectedly, mean area under the plasma concentration-time curve (AUC0-48h) and maximal plasma concentration (cmax) were slightly decreased following concomitant and short-term quercetin administration (3186.0 versus 2468.3 and 2527.7 ng h/ml, p>0.05; 309.7 versus 212.0 and 280.6 ng/ml, p>0.05). Individual analysis revealed that talinolol AUC0-48h was lowered by 23.9% up to 60.6% in 5 subjects and c…

AdultMaleATP Binding Cassette Transporter Subfamily BFlavonoidCmaxAdministration OralPharmaceutical SciencePharmacologyDrug Administration SchedulePropanolaminesYoung Adultchemistry.chemical_compoundPharmacokineticsHumansDrug Interactionsheterocyclic compoundsIntestinal MucosaP-glycoproteinchemistry.chemical_classificationCross-Over StudiesDose-Response Relationship DrugbiologyBiological TransportTransporterMiddle AgedHealthy VolunteersIntestineschemistrybiology.proteinFemaleQuercetinEffluxQuercetinTalinololEuropean Journal of Pharmaceutical Sciences
researchProduct

Effects of controlled-release on the pharmacokinetics and absorption characteristics of a compound undergoing intestinal efflux in humans

2006

Abstract Objective The number of active pharmaceutical ingredients (API) undergoing inhibitable and saturable intestinal efflux is considerable. As a consequence, absorption and bioavailability may depend on the intestinal concentration profile of the drug and may vary as a function of dose and release rate of the drug from the dosage form. The impact of controlled versus immediate-release on the absorption of P-glycoprotein substrates is currently unknown. Thus, the main focus of the present study was a comparison of the pharmacokinetics of the P-gp model substrate talinolol following administration of immediate-release (IR) and controlled-release (CR) tablets to healthy human volunteers w…

AdultMaleActive ingredientChemistryPharmaceutical ScienceAbsorption (skin)PharmacologyCrossover studyControlled releaseDosage formBioavailabilityPropanolamineschemistry.chemical_compoundIntestinal AbsorptionSolubilityPharmacokineticsDelayed-Action PreparationsHumansFemaleATP Binding Cassette Transporter Subfamily B Member 1TabletsTalinololEuropean Journal of Pharmaceutical Sciences
researchProduct

Differentiating explanations of attitude-consistent behavior: The role of perspectives and mode of perspective taking

2005

We examined whether participants could differentiate between explanations of attitude-consistent behavior related to EU membership given from two perspectives (EU supporter and EU opponent) by means of three perspective taking modes (the explainer's own perspective, imagined in-group members' perspective, and imagined out-group members' perspective). Participants were presented with explanations provided from different perspectives and perspective taking modes, and they were asked to judge the extent to which they agreed with each explanation, to guess the attitude of the provider of each explanation, and to rate the quality of each explanation in various respects. Participants could not di…

AdultMaleAnalysis of VarianceShared realitySocial IdentificationPoliticsPerspective (graphical)CognitionGeneral MedicineSupporterLatviaPsychology SocialMode (music)AttitudeSocial PerceptionArts and Humanities (miscellaneous)Perspective-takingDevelopmental and Educational PsychologyHumansQuality (philosophy)FemaleSocial BehaviorPsychologySocial psychologyGeneral PsychologyScandinavian Journal of Psychology
researchProduct

A phase II study of elacytarabine in combination with idarubicin and of human equilibrative nucleoside transporter 1 expression in patients with acut…

2013

Unlike cytarabine, cellular entry of Elacytarabine, the elaidic acid ester derivative of cytarabine, is independent of the human equilibrative nucleoside transporter 1 (hENT1). This phase II study tested whether the hENT1 blast expression level can be used as a predictive marker for cytarabine response and if the efficacy of elacytarabine is independent of hENT1 expression. A total of 51 patients with acute myeloid leukemia (AML) induction failure were given elacytarabine-idarubicin as a second induction course. The hENT1 expression level was analyzed prior to first induction and/or prior to treatment with elacytarabine. The overall response rate (ORR) was 41% and the safety profile was man…

AdultMaleCancer ResearchAdolescentPhases of clinical researchGene ExpressionPharmacologyNucleoside transporterEquilibrative nucleoside transporter 1Equilibrative Nucleoside Transporter 1Young AdultBone MarrowAntineoplastic Combined Chemotherapy ProtocolsmedicineIdarubicinHumansAgedPredictive markerbiologyElacytarabinebusiness.industryCytarabineHematopoietic Stem Cell TransplantationMyeloid leukemiaHematologyInduction ChemotherapyMiddle AgedLeukemia Myeloid AcuteTreatment OutcomeOncologybiology.proteinCytarabineFemalebusinessIdarubicinmedicine.drugLeukemialymphoma
researchProduct

Downregulation of organic cation transporter 1 (SLC22A1) is associated with tumor progression and reduced patient survival in human cholangiocellular…

2013

Cholangiocellular carcinoma (CCA) is a primary hepatic malignancy derived from cholangiocytes. The prognosis for CCA patients is very poor and conventional chemotherapy has been proven ineffective in improving long‑term patient survival rates. Organic cation transporters (OCTs) mediate the transport of a broad spectrum of endogenous substrates and the detoxification of xenobiotics. Moreover, OCTs are considered responsible for the responsiveness towards platinum‑based chemotherapies. Currently, there are no data available regarding the role of OCTs in CCA. Therefore, the aim of this study was to investigate the expression of OCT1 and OCT3 in CCA and the corresponding non-neoplastic tumor‑su…

AdultMaleCancer ResearchOrganic Cation Transport ProteinsDown-RegulationKaplan-Meier EstimateBiologySLC22A3CholangiocarcinomaDownregulation and upregulationWestern blotmedicineHumansRNA MessengerAgedAged 80 and overOncogenemedicine.diagnostic_testOrganic Cation Transporter 1CancerMiddle Agedmedicine.diseaseMolecular medicineBile Ducts IntrahepaticBile Duct NeoplasmsOncologyTumor progressionDisease ProgressionCancer researchbiology.proteinImmunohistochemistryFemaleNeoplasm Recurrence LocalInternational Journal of Oncology
researchProduct

Downregulation of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) in human hepatocellular carcinoma and their prognostic significance

2012

Abstract Background Organic cation transporters (OCT) are responsible for the uptake and intracellular inactivation of a broad spectrum of endogenous substrates and detoxification of xenobiotics and chemotherapeutics. The transporters became pharmaceutically interesting, because OCTs are determinants of the cytotoxicity of platin derivates and the transport activity has been shown to correlate with the sensitivity of tumors towards tyrosine kinase inhibitors. No data exist about the relevance of OCTs in hepatocellular carcinoma (HCC). Methods OCT1 (SLC22A1) and OCT3 (SLC22A3) mRNA expression was measured in primary human HCC and corresponding non neoplastic tumor surrounding tissue (TST) by…

AdultMaleCancer Researchmedicine.medical_specialtyCarcinoma HepatocellularOrganic Cation Transport ProteinsHepatocellular carcinomaBlotting WesternDown-RegulationOCT3Real-Time Polymerase Chain ReactionOCT1lcsh:RC254-282SLC22A3Downregulation and upregulationInternal medicineGeneticsmedicineHumansRNA MessengerHCCTyrosineSLC22A3CytotoxicitySLC22A1AgedAged 80 and overOrganic cation transport proteinsbiologybusiness.industryLiver NeoplasmsOrganic Cation Transporter 1TransporterMiddle AgedPrognosislcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseSurvival AnalysisNeoplasm ProteinsEndocrinologyOncologyHepatocellular carcinomaCancer researchbiology.proteinFemalebusinessTyrosine kinaseResearch ArticleBMC Cancer
researchProduct